EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAIVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY - Research portal of Justus Liebig University Giessen:

Meeting Abstract

EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAIVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY

Authors list: Kapetanovic, M. C.; Andersson, M.; Friedman, A.; Shaw, T.; Song, Y.; Aletaha, D.; Buch, M. H.; Mueller-Ladner, U.; Pope, J.

Publication year: 2020

Pages: 1007-1007

Journal: Annals of the Rheumatic Diseases

Volume number: 79

ISSN: 0003-4967

eISSN: 1468-2060

DOI Link: https://doi.org/10.1136/annrheumdis-2020-eular.1431

Conference: Annual European Congress of Rheumatology (EULAR)

Publisher: Elsevier

Citation Styles

Harvard Citation style: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., et al. (2020) EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAIVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY, Annals of the Rheumatic Diseases, 79, p. 1007. https://doi.org/10.1136/annrheumdis-2020-eular.1431

APA Citation style: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., Buch, M., Mueller-Ladner, U., & Pope, J. (2020). EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAIVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY. Annals of the Rheumatic Diseases. 79, 1007. https://doi.org/10.1136/annrheumdis-2020-eular.1431

SDG Areas

3 Good health and well-being